Background: T 2 -weighted imaging (T 2 -WI) information has been used in a qualitative manner in the assessment of prostate cancer. Quantitative derivatives (T 2 relaxation time) can be generated from T 2 -WI. These outputs may be useful in helping to discriminate clinically significant prostate cancer from background signal. Purpose/Hypothesis: To investigate changes in quantitative T 2 parameters in lesions and noncancerous tissue of men on active surveillance for prostate cancer taking dutasteride 0.5 mg or placebo daily for 6 months. Study Type: Retrospective. Population/Subjects: Forty men randomized to 6 months of daily dutasteride (n 5 20) or placebo (n 5 20). Field Strength/Sequence: Multiparametric 3T MRI at baseline and 6 months. This included a multiecho MR sequence for quantification of the T 2 relaxation times, in three regions of interest (index lesion, noncancerous peripheral [PZ] and transitional [TZ] zones). A synthetic signal contrast (T 2 Q contrast) between lesion and noncancerous tissue was assessed using quantitative T 2 values. Signal contrast was calculated using the T 2 -weighted sequence (T 2 W contrast). Assessment: Two radiologists reviewed the scans in consensus according to Prostate Imaging Reporting and Data System (PI-RADS v. 2) guidelines. Statistical Tests: Wilcoxon and Mann-Whitney U-tests, Spearman's correlation. Results: When compared to noncancerous tissue, shorter T 2 values were observed within lesions at baseline (83.5 and 80.5 msec) and 6 months (81.5 and 81.9 msec) in the placebo and dutasteride arm, respectively. No significant differences for T 2 W contrast at baseline and after 6 months were observed, both in the placebo (0.40 [0.29-0.49] vs. 0.43 [0.25-0.49]; P 5 0.881) and dutasteride arm (0.35 [0.24-0.47] vs. 0.37 [0.22-0.44]; P 5 0.668). There was a significant, positive correlation between the T 2 Q contrast and the T 2 W contrast values (r 5 0.786; P < 0.001). Data Conclusion: The exposure to antiandrogen therapy did not significantly influence the T 2 contrast or the T 2 relaxation values in men on active surveillance for prostate cancer.
M ultiparametric magnetic resonance imaging (mpMRI) combines high-resolution T 2 -weighted imaging (T 2 -WI) sequences with dynamic contrast-enhanced (DCE) and diffusion-weighted imaging (DWI), and/or spectroscopy. 1 Today, mpMRI plays a pivotal role in the diagnosis and risk stratification of men with prostate cancer. 2 The key sequences that drive this process are T 2 -WI and DWI, with DCE providing useful input in select cases. 3, 4 T 2 -WI generates a high signal-to-noise ratio (SNR) and confers high spatial resolution. These attributes permit the depiction of subglandular structures and for the differentiation of the zonal anatomy of the prostate (eg, peripheral/ transitional zone, seminal vesicles, neurovascular bundles, and urethra). 5, 6 The peripheral zone is characterized by high signal intensity on T 2 -WI, due to its higher water content, and cancer is frequently seen as an area of lower signal intensity. However, other conditions such as prostatitis, fibrosis, scar tissue, and postbiopsy hemorrhage may also cause low T 2 signal intensity, and result in false-positive diagnoses. 7 The degree of intensity decrease on T 2 -WI in the peripheral zone has been correlated with Gleason score, with higher Gleason scores having lower signal intensities. 8 T 2 -WI is also considered the most important sequence for the detection of cancer in the transitional zone according to recent guidelines, 9, 10 even though the heterogeneous appearance of benign prostate hyperplasia nodules in the transitional zone makes assessment for cancer challenging in this area. 11 Historically, T 2 -WI information has been used by radiologists in a qualitative manner and imputed into risk models such as the Prostate Imaging Reporting and Data System (PI-RADS). 9 However, quantitative derivatives (T 2 relaxation time) can also be generated from the T 2 -WI. These outputs may be useful in helping to discriminate clinically significant cancer from the background signal. Roebuck et al evaluated T 2 values on a pixel-by-pixel base using Carr-Purcell-Meiboom-Gill (CPMG) quantitative imaging, and found that prostate cancer shows a significantly shorter T 2 value when compared to healthy tissue. 12 It is known that dutasteride inhibits the enzyme 5-alpha-reductase, which converts testosterone to dihydrotestosterone, and is widely used for the treatment of lower urinary tract symptoms associated with an enlarged prostate. 13 Dutasteride is associated with a reduction of prostate volume, and there is evidence that dutasteride may delay the rate of progression in men on active surveillance for prostate cancer.
14 However, it is not known what effect dutasteride may have on the appearance of prostate cancer on T 2 -WI, and this is a clinically important information since mpMRI is gaining popularity as one of the assessment tools in patients on active surveillance.
In order to further evaluate the role of quantitative T 2 outputs, we undertook specific analyses on the T 2 -WI and multiecho CPMG sequences from men recruited into MAPPED-a randomized study of dutasteride versus placebo in men with low-risk prostate cancer on active surveillance, using mpMRI as an endpoint. 15 Our aim was to measure the T 2 relaxation time, a biomarker of tissue pathology, in cancerous and noncancerous tissue, and to examine the effect of dutasteride on those parameters.
Materials and Methods
This study was a retrospective analysis from a phase II, randomized, 15 The study was sponsored by University College London and GlaxoSmithKline (GSK) funded it through an unrestricted grant.
Eligibility Criteria and Study Design
All men gave their consent to participate in this study and the full protocol has been published. 15 16 All men included in this study did not have any prostate cancer treatment (hormone manipulation, prostatic surgery, and treatment with any 5-alpha reductase inhibitor) in the previous 12 months. A 3T MR scan including T 1 -and T 2 -W and DWI was performed and, after review by a study radiologist confirming suitability, men were individually randomized (1:1) to daily placebo or dutasteride using block randomization with varying block sizes. MpMRI was repeated at 6 months.
MRI
All patients underwent MRI on a 3T system (Magnetom Verio, Syngo MR B 17; Siemens Healthcare, Erlangen, Germany) and a pelvic phased-array coil. All examinations included unenhanced axial, sagittal, and coronal turbo spin-echo T 2 -WI, axial DWI (b values of 0, 100, 800, and 1400 s/mm 2 ) with reconstruction of the apparent diffusion coefficient (ADC) map and axial T 1 -WI during intravenous injection of 0.1 mmol/kg of body weight of gadoterate meglumine (Dotarem, Guerbet, Roissy, France) at a rate of 2 mL/s. The protocol was in line with standard guidelines. 17 Quantitative T 2 imaging was performed with a multiecho approach based on the CPMG imaging sequence. 12 The vendorsupplied CPMG sequence consisted of optimized 1808 sinc refocusing pulses, with spoiler gradients of constant amplitude applied around each refocusing pulse along the frequency-encoding direction. 18 The multiecho CPMG protocol was optimized to ensure a good compromise between several parameters; these included in-plane spatial resolution, sampling of the T 2 relaxation decay, the SNR, and the scan time.
Protocol optimization was carried out on three healthy volunteers; the CPMG sequence parameters chosen for the quantitative T 2 imaging of the current study are shown in Table 1 .
Image Analysis
All mpMRI data were anonymized. Two board-certified radiologists (A.K. and F.G., with 11 and 4 years of experience in prostate cancer mpMRI interpretation, respectively) reviewed the scans in consensus according to PI-RADS v. 2 guidelines, 9 using commercial image viewing software (Osirix v. 4.1.2; Geneva, Switzerland). Both readers were unaware of treatment allocation and were privy only to the date of the scan. To ensure consistency, all scans were reported in chronological order (ie, first baseline, and then 6-month scan). All lesions were visible on T 2 -WI (used as the reference standard) at baseline and after 6 months, and image quality was adequate in all patients. First, the two readers manually traced three regions of interest (ROIs) on the T 2 -W high-resolution images. The largest lesion (index tumor) was chosen, if multiple foci were detected in the same patient. The ROI was copied and pasted in the noncancerous peripheral (PZ) and transitional (TZ) zone, in mirror position to the lesion ( Fig. 1) on the same slice. The signal values from this sequence were defined as T 2 -W.
The three ROIs were then copied and pasted on the multiecho CPMG sequence. Quantitative T 2 data analysis of each ROI started with visual inspection of the T 2 relaxation decays. The signal of the first echo was observed to be lower than expected-at times even lower than the second echo. This is in line with previous observations on CPMG data. 12, 19 Thus, the signal of the first echo was omitted from the data analysis. T 2 values were estimated by fitting the signal S n obtained at the echo times TE n (n 5 2, 3,
where S 0 is a parameter proportional to the tissue proton density and external experimental factors. T 2 data fitting was performed using MatLab (MathWorks, Natick, MA). The T 2 values of the lesion, PZ, and TZ were determined both at baseline and after 6 months.
For each patient, we also measured the signal intensity of the lesion (S L ) and compared it to the signal intensity of presumed noncancer tissue in mirror position, ie, (S PZ ) for (S L ) in the PZ and (S TZ ) for (S L ) in the TZ on T 2 -WI. For example, we calculated the T 2 W contrast between a lesion in the PZ and the noncancerous tissue using the equation: T 2 W contrast 5 (S PZ -S L )/ S PZ . Furthermore, to investigate whether there was a correlation between the T 2 -W and the quantitative T 2 imaging data, we calculated a "synthetic" contrast using the T 2 values obtained from the CPMG data fitting. The calculation was as follows: first, we calculated the signal intensity that the lesion (with a T 2 obtained from quantitative T 2 imaging) would yield in the T 2 -W image. This was achieved by using the equation S 
Statistical Methods
Clinical and demographic data are reported using descriptive statistics. Continuous variables were summarized by their median values and interquartile range (IQR, 1 st quartile to 3 rd quartile); categorical variables were summarized by means of frequencies and percentages. We carried out the Wilcoxon signed-rank test to compare baseline and 6-month values (T 2 values and contrast), first in the placebo and then in the dutasteride group. The Mann-Whitney U-test was applied to investigate the differences between the two groups (placebo vs. dutasteride). The relationship between T 2 W and T 2 Q contrast was assessed by means of the Spearman's correlation coefficient. P < 0.05 was considered to indicate a significant difference. All statistical analyses were performed by using SPSS (v. 20.0; SPSS, Chicago, IL). All men had a positive biopsy at entry; specifically, 22/ 40 (55%) men had Gleason score 3 1 3 and 18/40 (45%) had Gleason 3 1 4. Of note, 37 of 40 men (93%) had histological confirmation of the mpMRI lesion contained cancer either at baseline or exit. Three men had discordant histology at baseline, one of whom had a negative exit biopsy (placebo group) and two who declined the exit biopsy (one placebo, one dutasteride). There was no difference in PSA values between the placebo and the dutasteride group at baseline (6.2 [5.3-7.8] vs. 6.4 [5.1-8.8] ng/mL, P 5 0.482), respectively. There was a significant difference in PSA values between the two arms after 6 months (6.6 [5.6-8] vs. 3.9 [2.2-5.6] ng/mL, P < 0.001). Table 2 compares median ROI measurements at baseline and after 6 months. There was a significant difference between baseline and 6-month ROI areas in the dutasteride arm (0.38 [0.27-0.61] vs. 0.27 [0.20-0.53] cm 2 ; P 5 0.005). Table 3 reports the comparison between T 2 values of lesions and noncancerous tissues (for PZ and TZ) at baseline and after 6 months. There was a significant difference (P < 0.001) between lesions and PZ for each arm, both at baseline and after 6 months (Fig. 2) . Table 4 reports the comparison for T 2 values from all ROIs for each of the two arms, at baseline and after 6 months. There were no significant differences both for lesions and noncancerous tissues (PZ and TZ). It should be noted that the median values in the PZ for the placebo arm at baseline were virtually the same as those after 6 months. The same finding was observed in the dutasteride arm. There was a significant, positive correlation between T 2 W and T 2 Q contrast values (r 5 0.786; P < 0.001), as shown in Fig. 4 .
Discussion
Our previous paper 20 showed a reduction in tumor volume on T 2 -WI in men on dutasteride for 6 months compared to men on placebo. A further article analyzing DWI 21 has
shown a reduction in conspicuity of prostate cancer in men on dutasteride for 6 months compared to placebo. In this article we report the analysis of dedicated research sequences, namely, quantitative T 2 imaging, at the same time as the anatomical T 2 -WI, but not previously analyzed. In contrast to the effect on DWI, the T 2 Q contrast values (quantitative) and the T 2 W contrast (qualitative) appear to be unaffected by exposure to dutasteride.
Quantitative T 2 imaging allows for measuring the T 2 relaxation time, a biomarker sensitive to tissue microenvironment. However, during a standard mpMRI of the prostate, only qualitative T 2 imaging (with a high SNR ratio and spatial resolution) is performed, to differentiate the zonal anatomy of the gland and the possible presence of cancer. 9 Cancerous tissue consists of highly compacted cells, and this results in a decrease in T 2 signal. 22 Although several recent studies have also evaluated the utility of quantitative T 2 imaging in prostate cancer, 12, [23] [24] [25] [26] [27] [28] [29] quantitative in vivo T 2 mapping is still a challenge due to the long scan duration, and therefore this approach is not routinely performed during a standard prostate mpMRI scan.
Our retrospective study aimed to fill this gap by analyzing a cohort of men on active surveillance exposed to dutasteride as part of the initial trial, who underwent a dedicated multiecho T 2 sequence in addition to the standard mpMRI. 15 The data acquisition protocol was optimized to yield the full volume coverage of the prostate, a good inplane spatial resolution, and a detailed sampling of the T 2 relaxation decay in order to obtain an accurate measurement of the T 2 relaxation time. The data analysis was performed on the ROIs, and data fitting was carried out offline with MatLab. It is known that antiandrogen therapy affects prostatic tissues, which inevitably affects the interpretation of mpMRI studies. The quantitative T 2 values are closely related to tissue properties and, in our study, they were not influenced by dutasteride. The P-values (Wilcoxon signed-rank test) for T2 comparison between L-PZ and L-TZ are also displayed. Data are medians with interquartile ranges in parentheses PZ: peripheral zone; TZ: transition zone. The correlation between the T 2 W and T 2 Q contrast provides insight into the results obtained from the qualitative and quantitative T 2 imaging data. Considerable variability of the contrast in the T 2 -WI was observed; same consideration applies to quantitative T 2 measurements, where different T 2 values were measured in different patients. Does this variability in T 2 -WI contrast and quantitative T 2 values originate from measurement error, or reflect true interindividual differences? The correlation found between the contrast measured on the T 2 -W images and the "synthetic" contrast calculated from the quantitative T 2 measurement indicates that the variability could be partly explained by interindividual differences. In other words, in patients with a high lesion contrast in the PZ (measured on T 2 -WI), the T 2 values measured by T 2 Q would have yielded T 2 -W images with a high contrast. Similarly, in patients with a low lesion contrast in the PZ, the T 2 values would have yielded T 2 -W images with a low contrast.
Starobinets et al 29 reported no significant differences in contrast on T 2 -WI between untreated and treated men. Similarly, we did not find any difference between the two arms, both at baseline and after 6 months of exposure to dutasteride. Following our definition of contrast, we could consider this parameter as a surrogate of the conspicuity of the lesion on T 2 -WI. It follows that the use of dutasteride does not seem to influence lesion conspicuity on T 2 -WI (ie, the lesion is still detectable after treatment). This finding is also supported by the significant difference in T 2 values from quantitative T 2 measurements between the lesion and noncancerous PZ for each arm, before and after treatment. It is known that visible lesions on mpMRI have an increased overall risk of cancer progression, so that identifying these lesions is of clinical importance. 30 Our results confirm that mpMRI can be used for reassessment during active surveillance in patients treated with 5-alpha-reductase inhibitors, as these medications do not affect signal intensity on quantitative and qualitative T 2 imaging, although our previous publication 20 suggests that 5-alphareductase inhibitors do result in a decrease in MRI-visible tumor volume. We agree with the PRECISE (Prostate Cancer Radiological Estimation of Change in Sequential Evaluation) recommendations 31 for reporting MRI in active surveillance that further studies are necessary to investigate exactly which imaging parameters (eg, tumor volume measurements on T 2 - WI) would be most appropriate to initiate repeat biopsy or indeed treatment. A number of methodological limitations in our study should be mentioned. First is the relatively small cohort of men. In mitigation, the men were all included in a prospective randomized controlled trial and therefore subject to standardized mpMRI and assessment. The study was of relatively short duration for a prostate cancer study, and therefore does not reflect the natural history of the condition. Second, some may regard the absence of tissue verification by means of radical prostatectomy step section pathological processing as a limitation. In this relatively low-risk population who had elected to enroll in an active surveillance study, few would choose to have surgery and therefore we would have to deal with missing data. The use of targeted biopsy-the reference test used in this study that could be applied to all men-has been shown to be as accurate as 5 mm template biopsy. 32 It is acknowledged that PZ and TZ tumors are scored differently according to PI-RADS v. 2 guidelines, 9 and our cohort was composed of 35 PZ and 5 TZ tumors. There is some likelihood that dissimilar evaluations would have arisen if the number of TZ lesions (more heterogeneous from a histological point of view) had been higher.
In conclusion, after this retrospective analysis, we found that T 2 relaxation times and T 2 -WI were not significantly influenced by the exposure to dutasteride in men on active surveillance for prostate cancer. This suggests that the drug may not impair our ability to measure tumor volume in active surveillance and longitudinal studies.
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